A formulation includes a carrier agent formed by conjugating at least one biologically active hydrophobic compound with at least one hydrophilic compound, the at least one biologically active hydrophobic compound selected from the group of farnesylthiosalicylic acid and a derivative of farnesylthiosalicylic acid which is biologically active as an RAS antagonist, wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via a linkage which is labile in vivo, and a biologically active compound associated with the carrier agent.

A copolymer, methods of making the polymer, methods of recycling the polymer and compositions including the polymer are described. The copolymer, can contain repeating units of Formula (I), and repeating units of Formula (II), for each of Formulas (I) and (II), n is independently 1 and denotes number of repeat units, X is an aliphatic group for each of Formulas (I) and (II), Z is a first polyolefin group comprising at least 45 carbon atoms, preferably 100 to 700 carbon atoms, and has a degree of saturation 98 to 100%; and Z is an aliphatic hydrocarbon group. Formula (I) or Formula (II), or both, comprise 0.01 to 40 ester groups per 1,000 backbone carbon atoms

A polymer film can be adjusted to movement or a fine uneven surface of a living body and has excellent ability to adhere to a biological tissue. The polymer film includes a block copolymer having a structure in which branched polyalkylene glycol and polyhydroxyalkanoic acid are bound to each other, wherein the polymer film has a film thickness of 10 to 1000 nm. The branched polyalkylene glycol has at least three terminal hydroxyl groups per molecule, the mass percentage of the branched polyalkylene glycol relative to the total mass of the block copolymer is 1% to 30%, and a value obtained by dividing the average molecular weight of polyhydroxyalkanoic acid in the block copolymer by X that is the number of terminal hydroxyl groups present per a single molecule of the branched polyalkylene glycol is 10000 to 30000.

The present invention relates to an amino polymer, its main chain is attached via a O group to a structure represented by the following formula (I). The present invention also relates to a process for producing said amino polymer and to its use as fuel oil detergent. Compared with the prior art, the fuel oil detergent of the present invention has the advantages such as a lower manufacturing cost and an improved deposit formation inhibition performance.

##STR00001##

In formula (I), groups and values are defined as described in the description.

A composition comprising: (a) from 20 to 60 wt % of a saccharide component comprising from two to five sugar ring units having polymerized units of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide and butylene oxide bonded to oxygen atoms on said sugar rings and at least three acetoacetyl groups bonded to terminal oxygen atoms of said polymerized units of at least one alkylene oxide; and (b) from 40 to 80 wt % of a non-saccharide component comprising a polyol unit not containing a sugar ring and having a hydroxyl functionality from two to five; said polyol unit having polymerized units of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide and butylene oxide bonded to hydroxyl oxygen atoms of the polyol and at least two acetoacetyl groups bonded to terminal oxygen atoms of said polymerized units of at least one alkylene oxide; wherein total polymerized units of at least one alkylene oxide comprise from 20 to 80 wt % of said multi-functional additive.

The present invention provides compounds represented by formula (I) and pharmaceutical acceptable salts thereof, preparation method therefor and pharmaceutical composition containing the compounds represented by formula (I) and pharmaceutical acceptable salts thereof. In the compounds of the present invention, each terminal group of polyethylene glycol molecule can bond with a plurality of rapamycin molecules by cactus oligopeptide, with the loading rate of the pharmaceutical being increased. The compounds can be used to induce immunosuppression and treat graft rejection, autoimmune disease, solid tumors, fungal infection, and cardiovascular and cerebrovascular disease. ##STR00001##

The present invention aims to provide a polymer capable of well dispersing hydrophobic particles. The present invention relates to a hydrophobic group-containing copolymer including a structural unit (A) derived from a hydrophobic group-containing monomer that is represented by the formula (1) and a structural unit (B) derived from a carboxylic acid-based monomer. The proportion of the structural unit (A) is from 16% by mass or more to 50% by mass or less based on 100% by mass of the structural units derived from all monomers constituting the copolymer, and the copolymer has a weight average molecular weight of 10,000 to 1,000,000.

##STR00001##

There is provided an anti-angiogenic agent comprising: a multi-block copolymer in the form of one or more micelles, wherein the copolymer comprises a first poly (alkylene glycol) block, a second poly (alkylene glycol) block and a polyester block. There is also provided a method of preparing said anti-angiogenic agent and medical uses of said anti-angiogenic agent.

A formulation includes a carrier agent formed by conjugating at least one biologically active hydrophobic compound with at least one hydrophilic compound, the at least one biologically active hydrophobic compound selected from the group of farnesylthiosalicylic acid and a derivative of farnesylthiosalicylic acid which is biologically active as an RAS antagonist, wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via a linkage which is labile in vivo, and a biologically active compound associated with the carrier agent.

A method of forming or creating a formulation for a compound to be delivered includes creating a carrier agent by conjugating at least one hydrophobic domain or hydrophobic compound with at least one hydrophilic domain or hydrophilic compound and associating the compound to be delivered with the carrier agent to create the formulation. The at least one hydrophobic compound has the formula: ##STR00001##
wherein R1 is a farnesyl group, a geranyl group or geranyl-geranyl group, X is O, S, SO, SO.sub.2, NH or Se, Z is CR.sub.2 or N, R.sub.2 is H, CN, CO.sub.2R.sub.7, SO.sub.3R.sub.7, CONR.sub.7R.sub.8 or SO.sub.2NR.sub.7R.sub.8, wherein R.sub.7 and R.sub.8 are each independently H, an alkyl group, an alkenyl group, CO.sub.2M or SO.sub.3M, wherein M is a cation and R.sub.3, R.sub.4, and R.sub.5 are independently H, a carboxyl group, an alkyl group, an alkenyl group, an aminoalkyl group, a nitroalkyl group, a nitro group, a halo atom, an amino group, a mono-alkylamino group, a di-alkylamino group, mercapto group, a mercaptoalkyl group, an azido group or a thiocyanato group. A plurality of the carrier agents are adapted to assemble into a structure. The hydrophobic compound is cleavably conjugated to the at least one hydrophilic compound via a linkage which is labile in vivo.